These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 35966310)
41. Validation of prognostic signature and exploring the immune-related mechanisms for Chen D; Yin Z; Chen Y; Bai Y; You B; Sun Y; Wu Y Transl Cancer Res; 2023 Oct; 12(10):2518-2532. PubMed ID: 37969386 [TBL] [Abstract][Full Text] [Related]
42. Up-regulated PIF1 predicts poor clinical outcomes and correlates with low immune infiltrates in clear cell renal cell carcinoma. Cai T; Wang N; Meng P; Sun W; Cui Y Front Genet; 2022; 13():1058040. PubMed ID: 36685888 [No Abstract] [Full Text] [Related]
43. STK4 is a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma. Bai ZY; Peng LS; Li RQ; Peng X; Yang Z Aging (Albany NY); 2023 Oct; 15(20):11286-11297. PubMed ID: 37870765 [TBL] [Abstract][Full Text] [Related]
44. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma. Zhang Y; Hua X; Shi H; Zhang L; Xiao H; Liang C Cancer Cell Int; 2021 Dec; 21(1):680. PubMed ID: 34923969 [TBL] [Abstract][Full Text] [Related]
45. P2RY13 is a prognostic biomarker and associated with immune infiltrates in renal clear cell carcinoma: A comprehensive bioinformatic study. Chu J; Liu W; Hu X; Zhang H; Jiang J Health Sci Rep; 2023 Dec; 6(12):e1646. PubMed ID: 38045624 [TBL] [Abstract][Full Text] [Related]
46. Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma. Huang S; Hou Y; Hu M; Hu J; Liu X BMC Cancer; 2022 Sep; 22(1):995. PubMed ID: 36123627 [TBL] [Abstract][Full Text] [Related]
47. High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis. Lei P; Zhang M; Li Y; Wang Z Front Genet; 2023; 14():996362. PubMed ID: 36999057 [No Abstract] [Full Text] [Related]
48. Caspase 4 Overexpression as a Prognostic Marker in Clear Cell Renal Cell Carcinoma: A Study Based on the Cancer Genome Atlas Data Mining. Meng L; Tian Z; Long X; Diao T; Hu M; Wang M; Zhang W; Zhang Y; Wang J; He Y Front Genet; 2020; 11():600248. PubMed ID: 33584797 [TBL] [Abstract][Full Text] [Related]
49. Analysis of Pyroptosis-Related Immune Signatures and Identification of Pyroptosis-Related LncRNA Prognostic Signature in Clear Cell Renal Cell Carcinoma. Zhong M; Wang X; Zhu E; Gong L; Fei L; Zhao L; Wu K; Tang C; Zhang L; Wang Z; Zheng Z Front Genet; 2022; 13():905051. PubMed ID: 35846134 [TBL] [Abstract][Full Text] [Related]
50. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633 [TBL] [Abstract][Full Text] [Related]
51. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma. Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462 [TBL] [Abstract][Full Text] [Related]
52. Multidimensional comprehensive and integrated analysis of the potential function of TMEM25 in renal clear cell carcinoma with low expression status. Xi P; Zhang Z; Liu Y; Nie Y; Gong B; Liu J; Huang H; Liu Z; Sun T; Xie W Aging (Albany NY); 2024 Jan; 16(1):367-388. PubMed ID: 38189809 [TBL] [Abstract][Full Text] [Related]
53. Development of a Novel KCNN4-Related ceRNA Network and Prognostic Model for Renal Clear Cell Carcinoma. Bu H; Song Q; Zhang J; Wei Y; Liu B Anal Cell Pathol (Amst); 2023; 2023():2533992. PubMed ID: 39282155 [TBL] [Abstract][Full Text] [Related]
54. Construction and validation of an m6A RNA methylation regulator prognostic model for early-stage clear cell renal cell carcinoma. Wang Z; Zhang M; Seery S; Zheng G; Wang W; Zhao Y; Wang X; Zhang Y Oncol Lett; 2022 Aug; 24(2):250. PubMed ID: 35761938 [TBL] [Abstract][Full Text] [Related]
55. The value of EYA1/3/4 in clear cell renal cell carcinoma: a study from multiple databases. Liu T; Nie J; Zhang X; Deng X; Fu B Sci Rep; 2023 May; 13(1):7442. PubMed ID: 37156847 [TBL] [Abstract][Full Text] [Related]
56. ITGB3 is a Novel Prognostic Biomarker and Correlates with Aberrant Methylation and Tumor Immunity in Clear Cell Renal Cell Carcinoma. Luo HY; Feng JM; Luo J; Tian T Comb Chem High Throughput Screen; 2024 Aug; ():. PubMed ID: 39136511 [TBL] [Abstract][Full Text] [Related]
57. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma. Mou Y; Wu J; Zhang Y; Abdihamid O; Duan C; Li B BMC Cancer; 2021 Jan; 21(1):18. PubMed ID: 33402128 [TBL] [Abstract][Full Text] [Related]
58. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma. Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779 [TBL] [Abstract][Full Text] [Related]
59. PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma. Wei X; Zhang X; Wang S; Wang Y; Ji C; Yao L; Song N Am J Cancer Res; 2022; 12(8):3780-3798. PubMed ID: 36119844 [TBL] [Abstract][Full Text] [Related]
60. Comprehensive Analysis of m Wu J; Hou C; Wang Y; Wang Z; Li P; Wang Z Int J Genomics; 2021; 2021():3803724. PubMed ID: 34631874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]